

## **Dr. Donna Skerrett Steps Down from Board Following Paradigm AGM**

**Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”)**, a late-stage drug development company, announces that Dr. Donna Skerrett has stepped down from her position as an Executive Director on the Board of the company, following the conclusion of yesterday’s Annual General Meeting (AGM).

Dr. Skerrett joined the Paradigm Board in July 2020 and has been an invaluable member throughout her tenure, providing expertise and leadership that have significantly contributed to the company’s progress and strategic initiatives.

Dr. Skerrett will continue to serve as Paradigm’s Chief Medical Officer (CMO), a role in which she remains instrumental to the company’s operations. Her focus will now intensify on the execution of Paradigm’s phase 3 clinical program and the subsequent New Drug Application (NDA) filing, key milestones in the company’s mission to bring innovative therapies to patients in need.

Paul Rennie, Paradigm Biopharmaceuticals’ Executive Chairman, expressed his gratitude for Dr. Skerrett’s contributions as a Board member, stating:

*"On behalf of the Board and the entire Paradigm team, I would like to extend my sincere thanks to Dr. Donna Skerrett for her exceptional service as an Executive Director. Donna's insights and dedication have been invaluable during a critical phase of the company's development. We are fortunate to continue benefiting from her expertise in her role as Chief Medical Officer as we advance our phase 3 program and work towards our NDA submission."*

Paradigm remains focused on delivering its strategic goals and looks forward to Dr. Skerrett’s continued contributions to its clinical and regulatory initiatives.

*-Ends-*

### **About Paradigm Biopharmaceuticals Ltd.**

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (**iPPS**) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

### **Forward Looking Statements**

This Company announcement contains forward-looking statements, including statements regarding anticipated commencement dates or completions dates of preclinical or clinical trials, regulatory developments and regulatory approval. These forward-looking

statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements.

To learn more please visit: <https://paradigmbiopharma.com>

Approved for release by the Paradigm Board of Directors.

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)

